GMCAII, NCT06221683: Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML |
|
|
| Recruiting | 2 | 500 | RoW | Homoharringtonine, Homoharringtonine injection, Cytarabine, Cytosar, Etoposide, Etoposide injection, Venetoclax, Venclexta, Mitoxantrone hydrochloride liposome, Mitoxantrone hydrochloride liposome injection, Recombinant Human Granulocyte Colony-Stimulating Factor, Recombinant Human Granulocyte Colony-Stimulating Factor Injection, Idarubicin Hydrochloride, Idarubicin hydrochloride injection, Sorafenib, Nexavar, Gilteritinib, Xospata Pill, Avapritinib, AYVAKIT | Children's Hospital of Soochow University | AML, Childhood, Acute Myeloid Leukemia | 12/28 | 12/29 | | |
NCT06316960: Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation |
|
|
| Recruiting | 2 | 50 | RoW | Avapritinib, AYVAKIT, Azacitidine Injection, Azacitidine, Decitabine Injection, Decitabine, Idarubicin Hydrochloride, Idarubicine, Cytarabine, CYTOSAR, Granulocyte Colony-Stimulating Factor, Recombinant Human Granulocyte Colony-Stimulating Factor Injection | Children's Hospital of Soochow University | AML, Childhood, Relapse/Recurrence, Refractory AML, Core Binding Factor Acute Myeloid Leukemia, C-KIT Mutation | 03/26 | 03/27 | | |
